CGS 25462

Drug Profile

CGS 25462

Latest Information Update: 16 Apr 1996

Price : $50

At a glance

  • Originator Novartis
  • Class Antihypertensives
  • Mechanism of Action Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 16 Apr 1996 Discontinued-II for Congestive heart failure in USA (PO)
  • 16 Apr 1996 Discontinued-II for Hypertension in USA (PO)
  • 03 Mar 1995 Phase-II clinical trials for Congestive heart failure in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top